Parion believes research is the engine that drives innovation in the life sciences and remains dedicated to our ongoing research and development efforts.  Our goal is to continue to discover and develop novel treatments for patients and ultimately commercialize our therapies.

Parion’s science driven technologies target respiratory diseases in which the patient’s ability to protect their mucosal surfaces is compromised.

Learn More About Our Pipeline

*For more information on individual programs, please see below.


ENaC Pulmonary (P-1037) “Also known as VX-371” = PHASE II tPAD CF = PHASE II Mucolytic = Preclinical CFTR Dry Eye (P-321) = Preclinical OPHTHALMOLOGYDry Eye (P-321) = PHASE II